In depth Zhiyao signed a comprehensive strategic cooperation agreement with China pharmaceutical, creating a new situation for AI pharmaceutical

Recently, China's local AI pharmaceutical R & D enterprise, dip, signed a comprehensive strategic cooperation agreement with China Pharmaceutical Health Industry Co., Ltd the two sides will apply for registration and application in AI innovative drug design and screening, knowledge map, AI drug synthesis, AI clinical trial, AI translation, AI pharmaceutical production and AI registration , intelligent supervision and other aspects of cooperation At the same time, the cooperation will rely on the small molecule drug discovery platform built by in-depth Zhiyao with powerful artificial intelligence technology to develop global innovative drugs at multiple targets The national 4 + 7 volume procurement has promoted the further transformation of China's generic pharmaceutical enterprises to innovative pharmaceutical enterprises Innovative medicine has ushered in a rare historical opportunity in China This is the first time that China's local AI pharmaceutical companies have joined hands with the national team to build an integrated intelligent R & D platform assembly line, and help the global pharmaceutical companies, especially China's pharmaceutical companies, accelerate their development in the period of industrial revolution In depth, Zhiyao will give full play to its advantages in the whole process of research and development, production and application of new drugs enabled by artificial intelligence technology In addition, China Pharmaceutical will give full play to its advantages in capital, equipment and market, and comprehensively promote research and development collaboration and deep integration of technological innovation High throughput screening and traditional virtual drug screening take a long time, and the success rate of drug development is low The emergence of artificial intelligence opens a new door for the discovery of innovative small molecule drugs In depth intelligent early drug discovery platform, it only takes 7-30 days from target discovery to screening 10-100 lead compounds, and the efficiency has been greatly improved It has cooperated with more than 20 pharmaceutical companies and research institutes at home and abroad in this field, with many successful cases At the same time, deepness Zhiyao selectively constructed a new drug-forming compound library by using the denovo platform (drug design from scratch), with an order of magnitude of 1020-1025, which greatly expanded the screening chemical space and reached the territory beyond the reach of human experts Artificial intelligence drug research and development will help drug companies significantly reduce the cost of research and development, accelerate the drug market, and improve the success rate of research and development LogP: lipid water partition coefficient; MW: molecular weight; MCFS: Medical Chemistry filters; vas: virtual screening; CPI: protein compound interaction; ADMET: drug absorption, distribution, metabolism, excretion and toxicity; * molecular library designed with denovo; * screening of synthesis difficulty is only required when screening with AI generation database China Medical and Health Industry Co., Ltd is a state-owned listed company listed on Shanghai Stock Exchange The company has established an integrated industrial pattern of science, industry and trade with international trade as the guide, pharmaceutical industry as the support and pharmaceutical commerce as the link The industrial pattern involves the whole industrial chain of R & D, planting and processing, production, distribution, logistics, import and export trade, academic promotion, technical services, etc The company has a leading domestic R & D and production platform for chemical APIs, an advanced domestic R & D and production platform for characteristic chemicals and modern traditional Chinese medicine, and is in a leading position in the R & D and production of anti infective and antiviral drugs as well as the planting and processing of licorice and other herbal medicines and products Dee Zhiyao is committed to enabling the whole process of new drug research and development with AI technology in the global scope In the early stage of drug discovery, the knowledge map based on AI technology (DI graphmed (E) Artificial intelligence small molecule drug discovery platform (DI draggoes) (E) , chemsynther (E) It can provide pharmaceutical enterprises and scientific research institutions with a complete set of solutions from project research, small molecule drug design, drug reuse, biomarker discovery and validation At the same time, the AI intelligent system and related services independently developed by Dee Zhiyao cover clinical research, pharmacovigilance, registration and application, medical translation and other fields At present, Dee Zhiyao is serving more than 190 global pharmaceutical enterprises, including Bayer, mosadong and other well-known old multinational pharmaceutical enterprises, and Baiji Shenzhou and other international innovative pharmaceutical enterprises It is an inevitable trend for AI to speed up the research and development of new drugs As a new force rising in China, Dee Zhiyao will practice the mission of "let the world have no difficult new drugs, bring light of hope to patients", become an intelligent infrastructure for global pharmaceutical companies and their service providers, provide more safe and effective products for patients, and bring new hope for the cure of diseases Jeni turtle